Independent Equity Research · Japan · TSE Prime

Kitazato Corporation

The Reproductive-Medicine Hidden Champion — Global Vitrification Standard-Setter

A 53% operating-margin IVF consumables franchise with the world’s leading vitrification (Cryotop®) and oocyte-retrieval-needle positions — now paying the price of margin mix, China base effects, and a single related-party channel that carries ~47% of sales.

¥1,466

Share price (2026-08-03)

¥586.4B

Market cap

15.1×

P/E (FY26 actual)

2.86×

P/B (FY26)

2.80%

Div. yield (¥41)

53.5%

FY26 OP margin

Code: 368A · Listed: 2025-06-25 (IPO ¥1,340, first close ¥2,001) · FY end: March · Industry: Medical devices / Reproductive medicine
Report date: 2026-08-03 · Data: FY2023–FY2026 actuals (有価証券報告書 / 決算短信 via ima), FY2027E company guidance, market data cross-checked from TSE/quotes

BUY — Margin-stabilization compounder at a 60%+ discount to global IVF peers

1 · Executive Summary 2 · Investment Thesis 3 · Financial Trajectory 4 · Business Deep Dive (7 dimensions) 5 · Segment Structure 6 · Anomaly Analysis 7 · Valuation 8 · Catalysts 9 · Risks 10 · Profit Quality 11 · Conclusion

Section 01

Executive Summary

Kitazato is a single-segment, consumables-driven maker of IVF & reproductive-medicine devices and reagents — the company that effectively wrote the book on oocyte/embryo vitrification (the Cryotop® method) and holds a global #1 share in oocyte-retrieval (OPU) needles.

What the company is

Business nature: consumables + reagents for the assisted-reproduction (ART) workflow — culture media, vitrification/warming media & devices, retrieval needles, embryo-transfer catheters, micro tools. Own-brand, made-in-Japan (Fuji, Shizuoka).
Structure: single operating segment (medical devices); revenue disclosed by 5 product categories and 6 geographies.
Scale: FY2026 net sales ¥10,947M, OP ¥5,858M (53.5% margin), net ¥3,895M; ~67% of sales exported to 110+ countries via ~80 distributors.
Governance: founder-CEO Futoshi Inoue controls ~58.5% via Kitazato & Co.; outside director Ignacio Bermejo is CEO of the two related-party distributors (IVIRMA Global group).

Why it matters now

Structural margin compression: gross margin 69.8%→65.9% and OP margin 58.7%→53.5% (FY24→FY26) on product-mix/OEM shift, new-plant depreciation and certification SG&A.
Engine switch: Media (culture media/reagents) is now the #1 category (+11.0% FY26, 36.6% of sales) — the growth engine — while flagship CryoDevices turned -2.6% on China’s spot-sale base effect.
Concentration: 46.6% of FY2026 sales flow through two related-party distributors that equal 100% of Europe and 100% of US revenue.
FY2027 guide: +3.6% sales / +4.4% OP (margin 53.9%) — stabilization, not acceleration; mid-term plan targets ¥33.3bn sales by FY2029, ¥20bn from new businesses.

Verdict preview: At ~15.1× FY26 P/E, ~2.86× P/B and ~7.5× EV/EBITDA with ¥13.4bn net cash, the market prices Kitazato as a Japan-listed micro-cap (vs Vitrolife 24–38× P/E). The margin mix, China base effect and related-party channel are known and guided; the moats (Cryotop standard, #1 OPU needle) are real. We rate BUY with a base-case target of ¥1,520 (15× FY27E EPS) and a bull case of ¥1,780.

Section 02

Investment Thesis

Thesis 1

Global standard-setter with compounding consumables economics

Cryotop® vitrification is the industry’s de-facto standard (≈60% share Japan, 70% Europe, 80% China, 85% India; >2M devices shipped 2023), and Kitazato is the global #1 in OPU needles (≈28%). Each IVF cycle consumes recurring media, devices and tools — defensive, per-cycle, low-cyclicality demand backed by late-childbearing demographics and insurance expansion (Japan since 2022).

Thesis 2

The growth engine has shifted to Media — and it is accelerating

Media (culture media/reagents/vitrification media) grew +11.0% in FY26 (≈62% of total growth) on Europe +15.7% and India +26.9%, with a global #5 position (≈8–11% share) behind Vitrolife’s ≈30%. The Ultra-Fast Warm FDA 510(k) (April 2026, survival 99.73%) unlocks US share — a second growth vector independent of the China spot cycle.

Thesis 3

Margin stabilization + capital return = re-rating fuel

Management guides OP margin to 53.9% in FY27E (vs 53.5% FY26) as OEM/certification costs moderate. With FY26 capex of only ¥239M, ¥13.4bn net cash and a payout ≥40% policy, dividend upside toward 50–70% payout is credible — a 2.8% yield that could approach 4% while the valuation stays 60%+ below global IVF peers.

Section 03

Financial Trajectory

A steady but decelerating compounder: ~5.4% revenue CAGR (FY23–26) with persistent margin compression that has cut OP margin from 58.7% (FY24) to 53.5% (FY26) — yet record absolute profits every year.

Consolidated P&L (¥M, unless noted)

Item	FY2023	FY2024	FY2025	FY2026	FY2027E
Net sales	9,348	10,080	10,302	10,947	11,346
YoY %	—	+7.8%	+2.2%	+6.3%	+3.6%
Gross profit	n/a	7,040	6,974	7,214	n/a
Gross margin %	—	69.8%	67.7%	65.9%	—
SG&A	n/a	1,127	1,191	1,355	n/a
Operating profit	5,128	5,912	5,782	5,858	6,115
OP margin %	54.9%	58.7%	56.1%	53.5%	53.9%
Ordinary profit	5,117	5,995	5,767	5,903	6,137
Net profit	3,370	3,972	3,788	3,895	4,059
Net margin %	36.0%	39.4%	36.8%	35.6%	35.8%
EPS (¥)	84.26	99.32	94.72	97.38	101.50
DPS (¥)	50.00	40.00	41.00	41.00	41.00
ROE %	25.9	26.4	22.1	20.1	—

FY2023 gross/SG&A not disclosed in the annual reports (key-indicator table only). EPS/DPS restated for the 200,000-for-1 split (2025-02-08). FY2025 includes a ¥25M remittance-fraud special loss; FY2026 includes ¥51M listing-related costs.

Revenue & operating margin trajectory

Volume / price / cost / mix commentary (per category, FY26)

Category	FY26 YoY	Primary driver	Volume/Price/Cost/Mix read
Media	+11.0%	Europe +15.7%, India +26.9%	Volume-led (new customers); prices maintained; group margin diluted by OEM/first-line SKU mix
CryoDevices	-2.6%	China spot-sale reversal	Volume (base effect); rest of world growing; high-margin franchise intact
Medical Devices	+8.1%	RYDEN™ ET catheter + OPU needle upgrades	Volume + mix (premium devices); own-brand, less OEM dilution
Micro Tools	+8.8%	ICSI workflow pull	Volume; registrations-led growth in US/EU
Other	+28.1%	Non-IVF lab items	Small base; immaterial

Key nuance: the fast-growing Media volume is not structurally low-margin — the mix drag comes from OEM/first-line SKUs and new-plant automation depreciation (COGS +12.2% in FY26, +13.8% guided at IPO). Gross profit still hit a record ¥7,214M. Incremental margin on new Media volume is below the corporate average — do not model linear profit leverage.

Section 04

Business Deep Dive

Seven dimensions across the three core product categories that drive the P&L (Media, CryoDevices, Medical Devices; Micro Tools as context).

D1 · Business essence
Product portfolio & business model

Category	Products	Type	FY26 ¥M / share
Media	Fertilization/sequential/single-step & blastocyst culture media, HEPES handling media, sperm-processing & PICSI/ICSI reagents, PVP, vitrification/warming media (Ultra-Fast Vitri/Warm, ES/VS/TS)	Consumables/reagents, own-brand, in-house R&D (Fuji)	4,004 / 36.6%
CryoDevices	Cryotop® (open vitrification), Repro dishes/plates, straws, ovarian-tissue freezing kit (2013), micro-sperm freezing kit (2022)	Consumables + devices, own-brand	3,081 / 28.1%
Medical Devices	OPU/retrieval needles (16–21G, double-lumen), ET catheters incl. RYDEN™ (fully echogenic, CE), IUI catheters, M-type pessary (Good Design 2013)	Devices, hand-finished precision, made-in-Japan	2,512 / 22.9%
Micro Tools	ICSI/micromanipulation pipettes, holding pipettes, microneedles	Consumables, precision	1,099 / 10.0%
Other	Non-IVF laboratory items	—	249 / 2.3%

Business model: own-brand consumables sold through ~80 distributors to 110+ countries (direct US arm Kitazato America since 2023). Subsidiaries: 北里バイオサイエンス (parts), 北里検査センター (genetic testing), 北里ヘルスケア (elder-care devices), 北里クライオバンク (cell/egg storage service — future profit pool). Founder Futoshi Inoue personally formulated media/reagents — media is the founder’s home turf.

D2 · Moat & market position
Where Kitazato actually wins

CryoDevices — the crown jewel

Cryotop® method co-developed with Kato Ladies Clinic (~2000) became the global standard of care after ~2005 adoption: ~60% Japan / 70% Europe / 80% China / 85% India share of vitrification sales; >2M devices shipped in 2023; >95% thaw survival; >65% of group sales tied to vitrification. Near-monopoly in open vitrification devices.

Medical Devices — #1 in OPU needles

#1 global share ~28% of oocyte-retrieval needles (2024) ahead of CooperSurgical & Vitrolife (≈40% combined). RYDEN™ ET catheter differentiates on fully-echogenic + atraumatic design (bubble position predicts pregnancy rate — a clinical-outcome moat).

Media — #5 global, evidence-driven switching costs

Global IVF media/oils share ≈8–11% (#5) behind Vitrolife ≈30%, CooperSurgical ~17–24%, Cook ~14–15%, FUJIFILM Irvine ~10–13%. Moat = clinical validation + protocol lock-in: labs standardize on proven brands because embryo-culture media correlates directly with outcomes. Regulatory moat: FDA 510(k) for Ultra-Fast Warm (K260248, Apr 2026; survival 99.73%, live birth 63.7% vs 57.0% multi-step).

Kitazato ~9% Vitrolife ~30% CooperSurgical ~20% Cook ~14% FUJIFILM Irvine ~11% Others ~16%

Sources: multiple 2025/26 market reports (datainsightsmarket, marketreportanalytics, pmarketresearch); ranges approximated.

D3 · Profit-driver decomposition
Volume / Price / Cost / Mix

Factor	Direction (FY26)	Detail
Volume	+6.3% revenue	Europe +15.7% (Media/Cryovice, RYDEN), India +26.9%, US +9.6%; Japan +4.7% recovery
Price	Neutral	Company aims to maintain prices; growth via top-hospital penetration, not pricing
Cost	Headwind	COGS +12.2% (¥3,732M): new-plant automation depreciation + raw materials; SG&A +13.8% (certifications, conferences, listing costs)
Mix	Headwind	Increase in OEM products + first-line SKUs raises COGS ratio; gross margin 65.9% (-180bp); OP margin 53.5% (-260bp)

Conclusion: the 53.5% OP margin is real and volume-driven, but the incremental margin on the fastest-growing Media volume is below the historical average because of OEM/first-line mix. Margin recovery in FY27E (guide 53.9%) depends on mix normalization — the single biggest profit-quality nuance in the model.

D4 · Demand structure & downstream
End markets, cyclicality, growth trajectory

Demand drivers

End market = IVF/ART clinics; Japan ~450k cycles/yr (world’s highest per capita; >10% of births via IVF); US ~300–400 clinics, growing.
Secular: late childbearing, ~1-in-6 global infertility, insurance expansion (Japan 2022, US state-by-state, EU subsidies), rising ICSI/PGT/blastocyst/freeze-all adoption.
Regional growth (company views): Europe 4–6% CAGR, US +7–10%/yr, India ~7.8–13.5%, China ~4.2% (2024–34), Japan roughly flat.

Defensive profile

Consumables tied to per-cycle usage = recurring, low-cyclicality. Not single-cycle dependent. Downside elasticity: distributor inventory adjustments (Korea/Taiwan FY26 3Q) and one-off spot sales (China FY25) create noisy YoY, but end demand is demographically defensive. Japan’s shrinking denominator is the structural headwind — offset by 67% export mix.

D5 · Capacity, capex & mid-term plan
Where the investment goes

Production: Fuji HQ plant (moved 2020) + Tokyo; new-plant automation commissioned ~FY2026 (source of the +13.8% COGS guide and future depreciation). No overseas manufacturing planned — explicit management stance.
Capex-light: FY2026 capex only ¥239M (vs ¥880M FY2025), depreciation ¥190M — an asset-light cash machine with ¥13.4bn cash and ~¥40M debt.
Mid-term plan (updated May 2026, FY2027–29): FY2029 sales target ¥33.3bn = existing core ~¥13.3bn + new areas ¥20bn (pharma, IVD, CryoBank, AI, clinic partnerships, M&A). Growth from here is increasingly adjacency/M&A-dependent.
Earlier 2028 targets: revenue ≥+4%/yr, overseas ratio →70%, OP margin ≥50% maintained, payout ≥40%.
FY2027 guide: sales ¥11,346M (+3.6%), OP ¥6,115M (+4.4%), OP margin 53.9% — stabilization as OEM/certification costs moderate.

D6 · Competition & risk
Who to watch, what could hurt

Category	Competitors	Risk emphasis
Media	Vitrolife (~30%, G5/EmbryoScope ecosystem), CooperSurgical, Cook, FUJIFILM Irvine ($30M capacity expansion), Gynemed, Nidacon, VitaVitro (China)	Price competition in Japan; OEM mix margin dilution; CE MDR/FDA cost; ~80-distributor reliance
CryoDevices	Vitrolife (Rapid-i™ closed system — main technology threat), CooperSurgical SAGE/VitriFit, FUJIFILM Irvine (Vit Kit), Genea Biomedx, VitaVitro	China local-content preference + VitaVitro push; closed-system contamination narrative vs open Cryotop
Medical Devices	Cook (EchoTip), Vitrolife (Sense; acquired a Japanese needle plant Aug 2025 — incursion into home market), CooperSurgical/Wallace, Rocket, RI.MOS.	Vitrolife’s local beachhead + 24–38× P/E war chest; certification delays (China ET catheter example)

Customer concentration (quantified): Biomedical Supply S.L. (Spain) ¥3,990M = 36.4% and Biomedical Supply US ¥1,120M = 10.2% of FY2026 sales — together 46.6%, and these equal 100% of Europe and 100% of US revenue. The growth engine and the concentration risk are the same name (IVIRMA Global entities, CEO = Kitazato outside director Bermejo).

D7 · Governance & capital return
Ownership, dividend, ROE trajectory

Signal	Detail
Controlling shareholder	Founder Futoshi Inoue via Kitazato & Co. ~58.5–58.9% — dual founder/CEO role = alignment + concentration; possible future stake-sale/liquidity measures flagged
Dividend	¥41/share FY26 (payout 42.1%), ¥41 planned FY27; policy payout ≥40%; MOI Global sees 50–70% payout plausible given ¥13.4bn net cash + capex-light model
ROE trajectory	26.4% (FY24) → 22.1% (FY25) → 20.1% (FY26) — declining with margin, still elite
Board	Outside director Ignacio Bermejo (Biomedical Supply/IVIRMA) — related-party oversight via special committee; auditor Ark Limited

Founder has publicly signaled dissatisfaction with post-IPO share performance — a return-of-capital pressure point that supports the dividend-upside thesis.

Section 05

Segment Structure

Single operating segment (medical devices); the P&L decomposes by product category and geography. Media overtook CryoDevices as the #1 category in FY2025 and widened the gap in FY2026.

Product mix (¥M) & share

Category	FY24	FY25	FY26	FY26 share
Media	3,566	3,607	4,004	36.6%
CryoDevices	2,878	3,165	3,081	28.1%
Medical Devices	2,499	2,324	2,512	22.9%
Micro Tools	958	1,009	1,099	10.0%
Other	177	194	249	2.3%
Total	10,080	10,302	10,947	100%

Geography (¥M)

Region	FY24	FY25	FY26	FY26 YoY
Japan	3,658	3,496	3,660	+4.7%
Europe	3,078	3,448	3,990	+15.7%
USA	950	1,022	1,120	+9.6%
China	922	868	672	-22.6%
India	517	467	593	+26.9%
Other	953	998	909	-8.9%
Total (overseas 66.6%)	10,080	10,302	10,947	+6.3%

FY2026 product mix & FY24→FY26 growth

Cross-foot: sum of categories and geographies both equal consolidated sales within ¥2–3M each year (rounding only) — internally consistent, no reconciliation puzzle.

Section 06

Anomaly Analysis

Eight deviations from trend, ordered by severity. Explanations sourced from ima RAG (search_knowledge) over the 有価証券報告書 / 決算短信.

#	Anomaly	Severity	Data point	Cause (management / RAG)
1	Gross-margin break 69.8%→67.7%→65.9%	High	FY26 65.9%	Product-mix deterioration + increase in OEM products (COGS ratio up); volume not the issue
2	OP margin 53.5% on +6.3% revenue	High	FY26	Mix/OEM dilution carried through + SG&A +13.8% (conferences, certifications, listing costs)
3	China -22.6% (¥868M→¥672M)	High	FY26	Reversal of FY2025 one-off spot sales — guided base effect (-24.1% guide), not structural collapse; main CryoDevices drag
4	FY2025 net -4.6% on +2.2% revenue	Med	FY25 ¥3,788M	~210bp gross-margin compression + ¥25M overseas remittance-fraud special loss + listing-prep costs
5	Related-party concentration 46.6%	High	FY26 ¥5,110M	Biomedical Supply S.L. (Spain) 36.4% + US 10.2% — = 100% of Europe + 100% of US revenue
6	CryoDevices -2.6% after +10.0%	Med	FY26 ¥3,081M	China spot-sale base effect (same driver as #3); all other categories above prior year
7	FY27E guide +4.4% OP (slowdown)	Med	FY27E 53.9%	Fourth straight year of sub-historical incremental margin; stabilization, not inflection
8	Stock split 200,000-for-1	Low	2025-02-08	Mechanical restatement of EPS/DPS series on 40,000,000-share base; no economic change

RAG query note: company-name-prefixed queries often returned title-only matches; body-text explanations retrieved by rephrasing without the leading company name. Anomalies 1, 3, 4, 5, 8 had direct explanations; 2, 6, 7 partial/inferred.

Section 07

Valuation

Current market data (2026-08-03, cross-checked: TSE quote / Matsui / Monex / finboard): price ¥1,466, market cap ¥58,640M, PER 15.1× (FY26 EPS 97.38) / 14.4× (FY27E EPS 101.50), PBR 2.86× (BPS 512.60), dividend yield 2.80% (¥41), net cash ~¥13,374M → EV/EBITDA ~7.5×.

Metric	Kitazato	Global IVF peer context
P/E (fwd)	14.4×	Vitrolife 24–38×; CooperSurgical 17.7–23.5× EV/EBIT
P/B	2.86×	ROE 20%+ justifies premium; micro-cap discount
EV/EBITDA	~7.5×	Net cash ¥13.4bn flatters the multiple
Div yield	2.80%	50–70% payout upside → ~4% potential
Analyst consensus TP	¥1,594 (12-mo)	Range ¥1,111–¥1,885 (glassgs, 81 analysts)

Scenario valuation (FY27E EPS basis)

Scenario	EPS (¥)	Multiple	Target (¥)	vs ¥1,466
Bear — margin compression persists, China stays weak	95.0	12×	1,140	-22%
Base — FY27E guide delivered, margin stabilizes	101.5	15×	1,520	+4%
Bull — Media re-accelerates + dividend hike + US FDA unlocks	105.0	17×	1,785	+22%

Valuation caveat: consensus sell/buy skew is mixed (glassgs rating score negative); the re-rating case rests on margin stabilization + dividend upside + new-business optionality (¥20bn of the FY2029 ¥33.3bn target is unproven).

Section 08

Catalysts

Near-term (0–12 months)

FY2027 1Q results (Aug 2026) — first read on margin stabilization and China base-effect normalization.
US FDA registrations for ET catheters / MicroTools — the stated US growth lever (US +9.6% FY26, guided +15.3% at IPO).
Ultra-Fast Warm FDA 510(k) commercial rollout (K260248, Apr 2026) — US cryo share unlock.
Dividend hike / payout raise toward 50–70% (net cash ¥13.4bn, capex ¥239M) — founder pressure for capital return.

Mid-term (1–3 years)

Mid-term plan execution (FY2029 ¥33.3bn) — ¥20bn from new areas: pharma, IVD, CryoBank, AI, clinic partnerships, M&A.
CryoBank service scale-up — recurring storage revenue + locked-in media/device usage (new profit pool).
US distributor de-concentration — potential new partner (DeviMed cited by MOI Global) reduces related-party dependence.
RYDEN™ ET catheter global penetration + OPU-needle share gains against Vitrolife’s Japanese incursion.

Section 09

Risks

High

Related-party channel concentration
46.6% of sales (100% of Europe + US) via IVIRMA Global distributors whose CEO sits on Kitazato’s board. Pricing-term disclosure is limited; any channel renegotiation or loss hits the two fastest-growing regions simultaneously.

High

Structural margin compression
Gross margin -3.9pp and OP margin -5.2pp since FY24. If OEM mix keeps rising and certification SG&A stays elevated, FY27E 53.9% guide fails and profit growth stalls near zero.

Med

China & CryoDevices swing
China -22.6% (2 straight down years) + local-content preference + VitaVitro. CryoDevices (-2.6%) is the flagship; its re-acceleration is upside, further weakness is the main downside.

Med

Vitrolife incursion & closed-system threat
Vitrolife bought a Japanese needle plant (Aug 2025) and markets the closed-system Rapid-i; contamination narrative pressures the open Cryotop format. Better-funded rival (24–38× P/E) now has a local beachhead.

Med

Regulatory & certification drag
CE MDR / FDA timelines gate US/EU growth; China ET-catheter certification delay (FY25) shows execution risk. Japan price competition persists (FY25 Japan -4.4%).

Low

Founder concentration & liquidity
~58.5% founder control = alignment but overhang; business-risk section flags possible further stake sales / share-liquidity measures.

Section 10

Profit Quality

Indicator	FY2023	FY2024	FY2025	FY2026	Read
Gross margin %	—	69.8	67.7	65.9	Compressing on mix/OEM — monitored
OP / ordinary ratio	—	98.6%	100.3%	99.2%	Near 100% — operating income is the core engine
Operating CF (¥M)	2,130	4,500	3,526	3,870	Strong; OCF/OP >66% every year
Free CF (¥M, est.)	~2,041	~4,411	~2,646	~3,633	Capex-light cash machine
ROE %	25.9	26.4	22.1	20.1	Declining with margin; still elite
Payout ratio %	—	—	—	43.3	Upside to 50–70% credible
Net cash (¥M)	8,099	10,474	11,460	13,414	Net cash > 22% of market cap

Overall assessment: profit quality is high — 99%+ of ordinary profit is operating, cash conversion is consistently >66% of OP, the balance sheet is 93.2% equity with ¥13.4bn net cash, and earnings are consumables-recurring. The two quality deductions are (1) incremental-margin dilution from OEM/first-line mix, and (2) one-off noise (FY25 ¥25M fraud loss, FY26 ¥51M listing costs). One-offs were manageable and are now largely normalized.

Section 11

Conclusion

Verdict: BUY · Time horizon: 12–24 months · Conviction: Medium-High

Kitazato is a world-class reproductive-medicine franchise — global standard in vitrification (Cryotop®), #1 in OPU needles, top-5 in IVF media — priced as a Japan micro-cap. The FY24–26 margin erosion, China base effect and related-party concentration are all disclosed, guided, and reversible; the moats are not. The base case (15× FY27E EPS = ¥1,520) offers ~4% upside with the dividend-upside and FDA catalysts providing asymmetry; the bull case is ¥1,785 (+22%).

Rating grid

Dimension	Score (1–5)	Comment
Business quality / moat	5	Cryotop standard + #1 OPU needle + consumables recurrence
Profit quality	4	99% operating, strong FCF, net cash — docked for mix dilution
Growth	3	+3.6% FY27E guide; Media engine real but incremental margin below average
Valuation	4	60%+ discount to global IVF peers; net cash >22% of cap
Governance / capital return	3.5	Founder-aligned, payout ≥40% — but related-party channel & overhang

Recommended actions

Core position for a 12–24-month horizon; add on weakness toward ¥1,200–1,300 (12–13× FY27E).
Triggers to re-evaluate: FY27 1Q margin print, China stabilization, any dividend-payout raise, US FDA registration progress, related-party channel changes.
De-risking triggers: further OEM-mix margin erosion below 53%, China decline accelerating, or governance concern on related-party pricing.
Watch items: mid-term ¥33.3bn FY2029 target execution (¥20bn new businesses = M&A dependency), Vitrolife’s Japanese manufacturing incursion, founder stake sales.

This report is an independent research artifact generated from company filings (via ima RAG) and public web sources. It is not investment advice. All market data as of 2026-08-03; company data FY2023–FY2026 actual, FY2027 company guidance.